Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
Rhea-AI Summary
Crescent Biopharma (Nasdaq: CBIO) priced an underwritten public offering of 8,094,793 ordinary shares and, in lieu of shares to certain investors, pre-funded warrants to purchase up to 525,897 ordinary shares. Ordinary shares are priced at $14.50 and pre-funded warrants at $14.499, with a $0.001 exercise price.
According to Crescent, expected gross proceeds are approximately $125 million before fees. Underwriters have a 30-day option to buy up to 1,293,103 additional shares. The offering is expected to close on July 16, 2026, subject to customary conditions, under an effective Form S-3 shelf registration.
Positive
- Approx. $125 million expected gross proceeds before fees from the offering
- Potential additional capital via 1,293,103-share underwriter option over 30 days
- All securities sold by Crescent, directly strengthening the company’s cash position
Negative
- Issuance of 8,094,793 new shares plus 525,897 pre-funded warrants dilutes existing shareholders
- Underwriters’ 30-day option for up to 1,293,103 extra shares adds further potential dilution
News Explained
The financing would dilute existing ownership if completed, with Crescent receiving gross rather than net proceeds; closing and final fees remain pending.
The July 14 release describes a priced, not-yet-closed financing; if completed, Crescent would issue the offered securities and receive the gross proceeds, while the shares and any exercised warrants would reduce existing holders’ percentage ownership.
The pre-funded warrants are priced nearly like shares and carry a nominal
In an underwritten offering, investment banks buy securities from the issuer and resell them; underwriting discounts and other expenses reduce net proceeds below the stated gross amount. On the first-quarter cash-use comparison, the proposed
The final prospectus supplement is the document to check for final size, price, and fees; the release expects closing on
Sources and calculations
- Crescent Biopharma public offering pricing release (2026-07-14)
- Dilution definition
- Pre-funded warrant definition
- Underwritten offering definition
- Prospectus supplement purpose
- Crescent Biopharma first-quarter fundamentals (2026Q1)
- Offering gross vs quarterly operating cash outflow, in days of cash use $125,000,000 / ($8,937,000 / 90) = [object Object]
- Cash and equivalents vs quarterly operating cash outflow, in days of cash use $189,163,000 / ($8,937,000 / 90) = [object Object]
News Market Reaction – CBIO
In the Jul 15 session, CBIO gained 2.38%, reflecting a moderate positive market reaction. Argus tracked a peak move of +7.2% during that session. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. Trading volume was very high at 4.7x the daily average, suggesting strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 26 | Inducement awards | Neutral | -3.0% | Granted stock options covering 65,100 shares as employment inducement awards. |
| Jun 11 | Inducement awards | Neutral | +0.6% | Granted stock options covering 23,550 shares to two non-executive employees. |
| Jun 02 | Conference presentations | Neutral | +5.7% | Planned management presentations at two June 2026 global healthcare conferences. |
| May 29 | Inducement awards | Neutral | -4.5% | Approved inducement stock options for 16,950 shares with time-based vesting. |
| May 21 | Clinical trial update | Positive | +2.5% | Announced ASCO 2026 Trial-in-Progress poster for ASCEND Phase 1/2 study. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent Crescent news has produced mixed single-day reactions, with both gains and declines following routine corporate and clinical updates.
Key Terms
pre-funded warrants financial
underwritten public offering financial
shelf registration statement regulatory
form s-3 regulatory
prospectus supplement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced the pricing of its underwritten public offering of 8,094,793 ordinary shares and in lieu of ordinary shares to certain investors, pre-funded warrants to purchase up to 525,897 ordinary shares. The ordinary shares are being sold to the public at a price of
Jefferies, TD Cowen, Guggenheim Securities and Cantor are acting as joint book-running managers for the offering. LifeSci Capital is acting as passive book-running manager for the offering.
The securities described above are being offered by Crescent pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed with the Securities and Exchange Commission (“SEC”) and was declared effective on July 10, 2026. A preliminary prospectus supplement and accompanying prospectus relating to this offering has been filed with the SEC and a final prospectus supplement and accompanying prospectus relating to this offering will be filed with the SEC. Copies of the final prospectus supplement and accompanying prospectus once filed will be accessible through the SEC’s website at www.sec.gov. The offering is being made only by means of a prospectus supplement and accompanying prospectus. Copies of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained, when available, by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at TDManualrequest@broadridge.com; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com; Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, NY 10022, or by email at prospectus@cantor.com; and LifeSci Capital LLC, Attention: LifeSci Capital LLC, 1700 Broadway, 40th Floor, New York, NY 10019, or by email at legalnotices@lifescicapital.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About Crescent Biopharma
Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies as single agents and as part of combination regimens to treat a range of solid tumors.
Forward-Looking Statements
Crescent cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to: our expectations regarding the expected closing of the offering and the potential exercise of the option to purchase additional ordinary shares. Actual results may differ from those set forth in this press release due to the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the offering, as well as risks and uncertainties inherent in our business described in our prior filings with the SEC, including under the heading “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2025, our quarterly report on Form 10-Q for the quarter ended March 31, 2026, and any subsequent current reports on Form 8-K or other filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contacts
Investors
Amy Reilly
Chief Communications Officer
amy.reilly@crescentbiopharma.com
617-465-0586
Media
Jenna Poist
Director, Corporate Communications
jenna.poist@crescentbiopharma.com
781-671-5019
